Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration
Objective: Anti‐Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr antigen remains unidentified. Methods: We used immunoprecipitation of total rat brain extract followed by mass spectrometry to identify...
Saved in:
Published in | Annals of neurology Vol. 71; no. 6; pp. 815 - 824 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.06.2012
Wiley-Liss Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective:
Anti‐Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr antigen remains unidentified.
Methods:
We used immunoprecipitation of total rat brain extract followed by mass spectrometry to identify the antigen recognized by anti‐Tr–positive sera. By Western blotting and cell‐based assays, we tested a total of 12 anti‐Tr–positive and 246 control sera and determined the region of the epitope recognized by the anti‐Tr antibodies. Deletion and mutant constructs were generated to further map the antigenic region.
Results:
Mass spectrometry analysis of immunopurified rat brain extract using 4 different anti‐Tr–positive sera led to the identification of Delta/Notch‐like epidermal growth factor‐related receptor (DNER) as the Tr antigen. All but 1 of 246 control samples were negative in the HeLa cell‐based screening assay, whereas 12 of the 12 anti‐Tr–positive sera stained hemagglutinin‐tagged DNER‐expressing cells. Only 1 control subject with HL but no ataxia was found to be both DNER and Tr positive. Using deletion constructs, we pinpointed the main epitope to the extracellular domain. Knockdown of endogenous DNER in hippocampal and N‐glycosylation mutations abolished the anti‐Tr staining, indicating that glycosylation of DNER is required for it to be recognized by anti‐Tr antibodies.
Interpretation:
DNER is the antigen detected by anti‐Tr–positive sera. Presence of anti‐Tr antibodies in patients with PCD and HL or HL only can now be screened quickly and reliably by using a cell‐based screening assay. ANN NEUROL 2012 |
---|---|
AbstractList | Objective: Anti-Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr antigen remains unidentified. Methods: We used immunoprecipitation of total rat brain extract followed by mass spectrometry to identify the antigen recognized by anti-Tr-positive sera. By Western blotting and cell-based assays, we tested a total of 12 anti-Tr-positive and 246 control sera and determined the region of the epitope recognized by the anti-Tr antibodies. Deletion and mutant constructs were generated to further map the antigenic region. Results: Mass spectrometry analysis of immunopurified rat brain extract using 4 different anti-Tr-positive sera led to the identification of Delta/Notch-like epidermal growth factor-related receptor (DNER) as the Tr antigen. All but 1 of 246 control samples were negative in the HeLa cell-based screening assay, whereas 12 of the 12 anti-Tr-positive sera stained hemagglutinin-tagged DNER-expressing cells. Only 1 control subject with HL but no ataxia was found to be both DNER and Tr positive. Using deletion constructs, we pinpointed the main epitope to the extracellular domain. Knockdown of endogenous DNER in hippocampal and N-glycosylation mutations abolished the anti-Tr staining, indicating that glycosylation of DNER is required for it to be recognized by anti-Tr antibodies. Interpretation: DNER is the antigen detected by anti-Tr-positive sera. Presence of anti-Tr antibodies in patients with PCD and HL or HL only can now be screened quickly and reliably by using a cell-based screening assay. ANN NEUROL 2012 Anti-Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr antigen remains unidentified.OBJECTIVEAnti-Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr antigen remains unidentified.We used immunoprecipitation of total rat brain extract followed by mass spectrometry to identify the antigen recognized by anti-Tr-positive sera. By Western blotting and cell-based assays, we tested a total of 12 anti-Tr-positive and 246 control sera and determined the region of the epitope recognized by the anti-Tr antibodies. Deletion and mutant constructs were generated to further map the antigenic region.METHODSWe used immunoprecipitation of total rat brain extract followed by mass spectrometry to identify the antigen recognized by anti-Tr-positive sera. By Western blotting and cell-based assays, we tested a total of 12 anti-Tr-positive and 246 control sera and determined the region of the epitope recognized by the anti-Tr antibodies. Deletion and mutant constructs were generated to further map the antigenic region.Mass spectrometry analysis of immunopurified rat brain extract using 4 different anti-Tr-positive sera led to the identification of Delta/Notch-like epidermal growth factor-related receptor (DNER) as the Tr antigen. All but 1 of 246 control samples were negative in the HeLa cell-based screening assay, whereas 12 of the 12 anti-Tr-positive sera stained hemagglutinin-tagged DNER-expressing cells. Only 1 control subject with HL but no ataxia was found to be both DNER and Tr positive. Using deletion constructs, we pinpointed the main epitope to the extracellular domain. Knockdown of endogenous DNER in hippocampal and N-glycosylation mutations abolished the anti-Tr staining, indicating that glycosylation of DNER is required for it to be recognized by anti-Tr antibodies.RESULTSMass spectrometry analysis of immunopurified rat brain extract using 4 different anti-Tr-positive sera led to the identification of Delta/Notch-like epidermal growth factor-related receptor (DNER) as the Tr antigen. All but 1 of 246 control samples were negative in the HeLa cell-based screening assay, whereas 12 of the 12 anti-Tr-positive sera stained hemagglutinin-tagged DNER-expressing cells. Only 1 control subject with HL but no ataxia was found to be both DNER and Tr positive. Using deletion constructs, we pinpointed the main epitope to the extracellular domain. Knockdown of endogenous DNER in hippocampal and N-glycosylation mutations abolished the anti-Tr staining, indicating that glycosylation of DNER is required for it to be recognized by anti-Tr antibodies.DNER is the antigen detected by anti-Tr-positive sera. Presence of anti-Tr antibodies in patients with PCD and HL or HL only can now be screened quickly and reliably by using a cell-based screening assay.INTERPRETATIONDNER is the antigen detected by anti-Tr-positive sera. Presence of anti-Tr antibodies in patients with PCD and HL or HL only can now be screened quickly and reliably by using a cell-based screening assay. Objective: Anti‐Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr antigen remains unidentified. Methods: We used immunoprecipitation of total rat brain extract followed by mass spectrometry to identify the antigen recognized by anti‐Tr–positive sera. By Western blotting and cell‐based assays, we tested a total of 12 anti‐Tr–positive and 246 control sera and determined the region of the epitope recognized by the anti‐Tr antibodies. Deletion and mutant constructs were generated to further map the antigenic region. Results: Mass spectrometry analysis of immunopurified rat brain extract using 4 different anti‐Tr–positive sera led to the identification of Delta/Notch‐like epidermal growth factor‐related receptor (DNER) as the Tr antigen. All but 1 of 246 control samples were negative in the HeLa cell‐based screening assay, whereas 12 of the 12 anti‐Tr–positive sera stained hemagglutinin‐tagged DNER‐expressing cells. Only 1 control subject with HL but no ataxia was found to be both DNER and Tr positive. Using deletion constructs, we pinpointed the main epitope to the extracellular domain. Knockdown of endogenous DNER in hippocampal and N‐glycosylation mutations abolished the anti‐Tr staining, indicating that glycosylation of DNER is required for it to be recognized by anti‐Tr antibodies. Interpretation: DNER is the antigen detected by anti‐Tr–positive sera. Presence of anti‐Tr antibodies in patients with PCD and HL or HL only can now be screened quickly and reliably by using a cell‐based screening assay. ANN NEUROL 2012 Objective: Anti-Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr antigen remains unidentified. Methods: We used immunoprecipitation of total rat brain extract followed by mass spectrometry to identify the antigen recognized by anti-Tr-positive sera. By Western blotting and cell-based assays, we tested a total of 12 anti-Tr-positive and 246 control sera and determined the region of the epitope recognized by the anti-Tr antibodies. Deletion and mutant constructs were generated to further map the antigenic region. Results: Mass spectrometry analysis of immunopurified rat brain extract using 4 different anti-Tr-positive sera led to the identification of Delta/Notch-like epidermal growth factor-related receptor (DNER) as the Tr antigen. All but 1 of 246 control samples were negative in the HeLa cell-based screening assay, whereas 12 of the 12 anti-Tr-positive sera stained hemagglutinin-tagged DNER-expressing cells. Only 1 control subject with HL but no ataxia was found to be both DNER and Tr positive. Using deletion constructs, we pinpointed the main epitope to the extracellular domain. Knockdown of endogenous DNER in hippocampal and N-glycosylation mutations abolished the anti-Tr staining, indicating that glycosylation of DNER is required for it to be recognized by anti-Tr antibodies. Interpretation: DNER is the antigen detected by anti-Tr-positive sera. Presence of anti-Tr antibodies in patients with PCD and HL or HL only can now be screened quickly and reliably by using a cell-based screening assay. ANN NEUROL 2012 [PUBLICATION ABSTRACT] Anti-Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr antigen remains unidentified. We used immunoprecipitation of total rat brain extract followed by mass spectrometry to identify the antigen recognized by anti-Tr-positive sera. By Western blotting and cell-based assays, we tested a total of 12 anti-Tr-positive and 246 control sera and determined the region of the epitope recognized by the anti-Tr antibodies. Deletion and mutant constructs were generated to further map the antigenic region. Mass spectrometry analysis of immunopurified rat brain extract using 4 different anti-Tr-positive sera led to the identification of Delta/Notch-like epidermal growth factor-related receptor (DNER) as the Tr antigen. All but 1 of 246 control samples were negative in the HeLa cell-based screening assay, whereas 12 of the 12 anti-Tr-positive sera stained hemagglutinin-tagged DNER-expressing cells. Only 1 control subject with HL but no ataxia was found to be both DNER and Tr positive. Using deletion constructs, we pinpointed the main epitope to the extracellular domain. Knockdown of endogenous DNER in hippocampal and N-glycosylation mutations abolished the anti-Tr staining, indicating that glycosylation of DNER is required for it to be recognized by anti-Tr antibodies. DNER is the antigen detected by anti-Tr-positive sera. Presence of anti-Tr antibodies in patients with PCD and HL or HL only can now be screened quickly and reliably by using a cell-based screening assay. |
Author | Hoogenraad, Casper C. Demmers, Jeroen Sillevis Smitt, Peter Hulsenboom, Esther van den Bent, Martin Maat, Peter van den Berg, Robert Lugtenburg, Pieternella J. de Graaff, Esther |
Author_xml | – sequence: 1 givenname: Esther surname: de Graaff fullname: de Graaff, Esther organization: Cell Biology, Faculty of Science, Utrecht University, Utrecht – sequence: 2 givenname: Peter surname: Maat fullname: Maat, Peter organization: Neurology, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 3 givenname: Esther surname: Hulsenboom fullname: Hulsenboom, Esther organization: Neurology, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 4 givenname: Robert surname: van den Berg fullname: van den Berg, Robert organization: Cell Biology, Faculty of Science, Utrecht University, Utrecht – sequence: 5 givenname: Martin surname: van den Bent fullname: van den Bent, Martin organization: Neurology, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 6 givenname: Jeroen surname: Demmers fullname: Demmers, Jeroen organization: Biochemistry, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 7 givenname: Pieternella J. surname: Lugtenburg fullname: Lugtenburg, Pieternella J. organization: Hematology, Erasmus Medical Center, Rotterdam, the Netherlands – sequence: 8 givenname: Casper C. surname: Hoogenraad fullname: Hoogenraad, Casper C. email: c.hoogenraad@uu.nl organization: Cell Biology, Faculty of Science, Utrecht University, Utrecht – sequence: 9 givenname: Peter surname: Sillevis Smitt fullname: Sillevis Smitt, Peter email: p.sillevissmitt@erasmusmc.nl organization: Neurology, Erasmus Medical Center, Rotterdam, the Netherlands |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26006745$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22447725$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkl1rFDEUhgep2G31wj8gARH0Yrr5nMxcLsV2K0sFrQjehGzmpJs2OzMmWdr-gv5ts18KRfEqITzve95zco6Kg67voCheE3xCMKZj3ekTyoTAz4oREYyUNeXNQTHCrOKlIIwfFkcx3mCMm4rgF8UhpZxLScWoeLxooUvOOqOT6zvUW9SCT3rc9cksSu9uAcHgWghL7dF16O_SAlltUh_KAF4naFEAA0N-QDqitAB0lW_Z8xo65Do06KA76AevY3IGGQgwB-91yIUyAmFT-GXx3Gof4dXuPC6-nX28Op2Ws8_nF6eTWWlE7q_kjdTcktqKloAgNdTM5J6EbOq2mgtjKgk1oZbatpa1oVXFGGW15PPWgmwxOy7eb32H0P9cQUxq6aJZ58kZV1ERQTFrcM34_1FMSVNjKZuMvn2C3vSr0OVGsiGpuBSSs0y92VGr-RJaNQS31OFB7X8jA-92gI5Ge5sHZ1z8w1UYV5KvufGWM6GPMYBVxqXNGFPQzudkar0XKu-F2uxFVnx4otib_o3dud85Dw__BtXkcrJXlFuFiwnufyt0uFWVZFKo75fn6mw6-_pFTD-pH-wX4djVpw |
CODEN | ANNED3 |
CitedBy_id | crossref_primary_10_1517_21678707_2014_903796 crossref_primary_10_1212_NXI_0000000000000178 crossref_primary_10_1007_s12311_021_01363_3 crossref_primary_10_1186_s12974_015_0358_9 crossref_primary_10_3390_jcm14020364 crossref_primary_10_1186_s12883_021_02403_5 crossref_primary_10_1212_NXI_0000000000000294 crossref_primary_10_3390_brainsci11111414 crossref_primary_10_3390_brainsci12020257 crossref_primary_10_1016_j_neurol_2024_07_003 crossref_primary_10_1111_ejn_13212 crossref_primary_10_1136_practneurol_2021_003073 crossref_primary_10_1007_s12311_021_01346_4 crossref_primary_10_1007_s10072_022_06389_x crossref_primary_10_1016_j_neuron_2015_11_012 crossref_primary_10_1038_s41571_019_0194_4 crossref_primary_10_1212_CPJ_0b013e31826af23e crossref_primary_10_3389_fimmu_2022_850540 crossref_primary_10_3988_jcn_2016_12_1_1 crossref_primary_10_1016_j_msard_2013_12_001 crossref_primary_10_1007_s11940_013_0220_2 crossref_primary_10_1016_j_autrev_2013_10_016 crossref_primary_10_5692_clinicalneurol_cn_001314 crossref_primary_10_1016_j_clml_2021_09_023 crossref_primary_10_1111_cei_12185 crossref_primary_10_1001_jamaneurol_2024_2008 crossref_primary_10_1007_s12311_024_01711_z crossref_primary_10_1007_s00115_012_3607_5 crossref_primary_10_1186_s42466_019_0037_x crossref_primary_10_3389_fnmol_2016_00037 crossref_primary_10_1212_NXI_0000000000001014 crossref_primary_10_1016_j_path_2014_10_005 crossref_primary_10_1007_s00702_014_1193_3 crossref_primary_10_1016_j_revmed_2016_10_396 crossref_primary_10_3389_fimmu_2020_00991 crossref_primary_10_1093_brain_awz094 crossref_primary_10_3389_fneur_2021_744653 crossref_primary_10_1007_s11864_013_0249_1 crossref_primary_10_1515_revneuro_2017_0081 crossref_primary_10_1056_NEJMra1708712 crossref_primary_10_1097_CCO_0000000000000222 crossref_primary_10_3988_jcn_2022_18_4_373 crossref_primary_10_1007_s00115_014_4030_x crossref_primary_10_1007_s12311_022_01468_3 crossref_primary_10_1007_s12013_014_0202_3 crossref_primary_10_1007_s00262_013_1442_6 crossref_primary_10_1093_brain_awx189 crossref_primary_10_1080_14737175_2021_1927713 crossref_primary_10_1016_S1474_4422_12_70301_0 crossref_primary_10_1212_NXI_0000000000000156 crossref_primary_10_1007_s12311_023_01550_4 crossref_primary_10_1002_acn3_396 crossref_primary_10_1186_s12974_015_0356_y crossref_primary_10_1371_journal_pone_0161157 crossref_primary_10_1038_s41582_023_00776_4 crossref_primary_10_4236_wjns_2023_131004 crossref_primary_10_1016_j_neurol_2014_07_007 crossref_primary_10_1007_s12311_023_01636_z crossref_primary_10_1002_pbc_31594 crossref_primary_10_1136_jnnp_2024_333458 crossref_primary_10_1177_0883073816685505 crossref_primary_10_3389_fimmu_2022_854445 crossref_primary_10_1007_s10072_022_06083_y crossref_primary_10_1053_j_semdp_2019_06_005 crossref_primary_10_1093_clinchem_hvaa254 crossref_primary_10_1212_NXI_0000000000000068 crossref_primary_10_3390_biomedicines11051406 crossref_primary_10_1212_NXI_0000000000000987 crossref_primary_10_5301_ijao_5000435 crossref_primary_10_1016_S1634_7072_22_46429_4 crossref_primary_10_1089_cbr_2018_2460 crossref_primary_10_1080_1744666X_2019_1573676 crossref_primary_10_1212_WNL_0000000000009242 crossref_primary_10_1002_pnp_812 crossref_primary_10_1016_j_autrev_2016_07_024 crossref_primary_10_1186_s40673_021_00137_1 crossref_primary_10_1007_s10072_017_3031_5 crossref_primary_10_1016_j_jclinane_2013_03_014 crossref_primary_10_1182_blood_2014_03_537506 crossref_primary_10_1186_s12974_014_0206_3 crossref_primary_10_1007_s00277_023_05357_5 crossref_primary_10_1016_j_conb_2017_07_012 crossref_primary_10_1097_WCO_0b013e328359da15 crossref_primary_10_1186_s42466_020_0053_x crossref_primary_10_1016_j_autrev_2019_102422 crossref_primary_10_1007_s11912_018_0721_y crossref_primary_10_2169_internalmedicine_4530_24 crossref_primary_10_1152_physrev_00010_2016 crossref_primary_10_1007_s42451_025_00720_4 crossref_primary_10_1007_s10072_022_05955_7 crossref_primary_10_1016_j_jns_2020_117103 crossref_primary_10_1007_s00415_012_6657_5 crossref_primary_10_1016_j_nerep_2022_100161 crossref_primary_10_1212_NXI_0000000000200018 |
Cites_doi | 10.1074/jbc.M110793200 10.1007/s004010050853 10.1212/WNL.53.8.1719 10.1016/S1474-4422(08)70060-7 10.1212/WNL.42.10.1938 10.1212/WNL.0b013e31820d62eb 10.1002/ana.21050 10.1016/S1474-4422(09)70324-2 10.1634/theoncologist.11-3-292 10.1212/WNL.0b013e3182364a44 10.1212/01.WNL.0000041495.87539.98 10.1002/ana.21589 10.1001/archneur.1976.00500090066014 10.1016/j.devcel.2007.02.006 10.1523/JNEUROSCI.0167-10.2010 10.1097/00001756-200205070-00035 10.1056/NEJM199006283222604 10.1016/S0165-5728(96)00205-6 10.1200/JCO.1997.15.8.2866 10.1038/nn1492 10.1136/jnnp.29.1.45 10.1016/j.mcn.2005.10.003 10.1016/S1474-4422(10)70137-X 10.1093/brain/awg133 10.1056/NEJM200001063420104 10.1093/brain/awq113 |
ContentType | Journal Article |
Copyright | Copyright © 2012 American Neurological Association 2015 INIST-CNRS Copyright © 2012 American Neurological Association. |
Copyright_xml | – notice: Copyright © 2012 American Neurological Association – notice: 2015 INIST-CNRS – notice: Copyright © 2012 American Neurological Association. |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TK 7U7 C1K K9. 7X8 |
DOI | 10.1002/ana.23550 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Toxicology Abstracts Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Neurosciences Abstracts MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1531-8249 |
EndPage | 824 |
ExternalDocumentID | 3276327921 22447725 26006745 10_1002_ana_23550 ANA23550 ark_67375_WNG_FHLSR5HJ_Z |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OB 1OC 1ZS 23M 2QL 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAEJM AAESR AAEVG AAHHS AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABIVO ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBMB ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRZS ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFAZI AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE AJJEV ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM EBS EJD EMOBN F00 F01 F04 F5P F8P FEDTE FUBAC FYBCS G-S G.N GNP GODZA GOZPB GRPMH H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M J5H JPC KBYEO KD1 KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LXL LXN LXY LYRES M6M MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ NNB O66 O9- OHT OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.- Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWD RWI RX1 SAMSI SJN SUPJJ TEORI UB1 V2E V8K V9Y VH1 W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 XJT XPP XSW XV2 YOC YQJ ZGI ZRF ZRR ZXP ZZTAW ~IA ~WT ~X8 AAHQN AAIPD AAMMB AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AEFGJ AEYWJ AFWVQ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY ALVPJ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TK 7U7 C1K K9. 7X8 |
ID | FETCH-LOGICAL-c5550-497a4f18f5d1e518e83c9615798d6b5cc67e812f2fd878c2663323874bdfe7d03 |
IEDL.DBID | DR2 |
ISSN | 0364-5134 1531-8249 |
IngestDate | Thu Jul 10 22:33:59 EDT 2025 Fri Jul 11 02:19:42 EDT 2025 Fri Jul 25 12:14:13 EDT 2025 Thu Apr 03 07:05:27 EDT 2025 Mon Jul 21 09:14:53 EDT 2025 Tue Jul 01 02:24:02 EDT 2025 Thu Apr 24 22:54:59 EDT 2025 Wed Aug 20 07:25:47 EDT 2025 Wed Oct 30 09:58:28 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Cerebellum Nervous system diseases Growth factor receptor Epidermal growth factor Central nervous system Degeneration Paraneoplastic syndrome Encephalon |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 Copyright © 2012 American Neurological Association. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5550-497a4f18f5d1e518e83c9615798d6b5cc67e812f2fd878c2663323874bdfe7d03 |
Notes | ark:/67375/WNG-FHLSR5HJ-Z istex:50756376CC37A6FFA4878345709A050851CBC7B9 ArticleID:ANA23550 Potential Conflicts of Interest Nothing to report. Nothing to report. Potential Conflicts of Interest ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://hdl.handle.net/1765/58576 |
PMID | 22447725 |
PQID | 1516475743 |
PQPubID | 946345 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1520390834 proquest_miscellaneous_1021980779 proquest_journals_1516475743 pubmed_primary_22447725 pascalfrancis_primary_26006745 crossref_citationtrail_10_1002_ana_23550 crossref_primary_10_1002_ana_23550 wiley_primary_10_1002_ana_23550_ANA23550 istex_primary_ark_67375_WNG_FHLSR5HJ_Z |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | June 2012 |
PublicationDateYYYYMMDD | 2012-06-01 |
PublicationDate_xml | – month: 06 year: 2012 text: June 2012 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: Hoboken, NJ – name: United States – name: Minneapolis |
PublicationTitle | Annals of neurology |
PublicationTitleAlternate | Ann Neurol |
PublicationYear | 2012 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss – name: Wiley Subscription Services, Inc |
References | Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126: 1409-1418. Graus F, Dalmau J, Valldeoriola F, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74: 55-61. Sillevis Smitt P, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342: 21-27. Keime-Guibert F, Graus F, Broet P, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 1999; 53: 1719-1723. Hammack J, Kotanides H, Rosenblum MK, et al. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 1992; 42: 1938-1943. Nishizumi H, Komiyama T, Miyabayashi T, et al. BET, a novel neuronal transmembrane protein with multiple EGF-like motifs. Neuroreport 2002; 13: 909-915. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30: 5866-5875. Eiraku M, Hirata Y, Takeshima H, et al. Delta/Notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to dendrites of developing and adult central nervous system neurons. J Biol Chem 2002; 277: 25400-25407. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67-76. Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15: 2866-2872. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7: 327-340. Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60: 230-234. Horwich L, Buxton PH, Ryan GM. Cerebellar degeneration with Hodgkin's disease. J Neurol Neurosurg Psychiatry 1966; 29: 45-51. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667. Briani C, Vitaliani R, Grisold W, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011; 76: 705-710. Hoogenraad CC, Feliu-Mojer MI, Spangler SA, et al. Liprinalpha1 degradation by calcium/calmodulin-dependent protein kinase II regulates LAR receptor tyrosine phosphatase distribution and dendrite development. Dev Cell 2007; 12: 587-602. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785. Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322: 1844-1851. Eiraku M, Tohgo A, Ono K, et al. DNER acts as a neuron-specific Notch ligand during Bergmann glial development. Nat Neurosci 2005; 8: 873-880. Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin disease. An immunological study. Arch Neurol 1976; 33: 660-661. Posner JB. Paraneoplastic syndromes. Philadelphia, PA: F.A. Davis, 1995. Graus F, Gultekin SH, Ferrer I, et al. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol 1998; 96: 1-7. de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist 2006; 11: 292-305. Tohgo A, Eiraku M, Miyazaki T, et al. Impaired cerebellar functions in mutant mice lacking DNER. Mol Cell Neurosci 2006; 31: 326-333. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011; 77: 1698-1701. 2006; 31 2009; 65 2006; 11 2002; 13 2002; 277 2011; 77 2008; 7 1995 2011; 76 1990; 322 2007; 12 1966; 29 1976; 33 1997; 74 1997; 15 2005; 8 2010; 133 1999; 53 2007; 61 2000; 342 2003; 126 1998; 96 2003; 60 1992; 42 2010; 30 2010; 9 e_1_2_6_18_2 e_1_2_6_19_2 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_10_2 e_1_2_6_11_2 e_1_2_6_16_2 e_1_2_6_17_2 e_1_2_6_14_2 e_1_2_6_15_2 e_1_2_6_20_2 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_24_2 e_1_2_6_23_2 e_1_2_6_22_2 e_1_2_6_21_2 e_1_2_6_28_2 e_1_2_6_27_2 Posner JB (e_1_2_6_2_2) 1995 e_1_2_6_26_2 e_1_2_6_25_2 |
References_xml | – reference: Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7: 327-340. – reference: Posner JB. Paraneoplastic syndromes. Philadelphia, PA: F.A. Davis, 1995. – reference: Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126: 1409-1418. – reference: Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434. – reference: Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30: 5866-5875. – reference: Graus F, Gultekin SH, Ferrer I, et al. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. Acta Neuropathol 1998; 96: 1-7. – reference: Eiraku M, Hirata Y, Takeshima H, et al. Delta/Notch-like epidermal growth factor (EGF)-related receptor, a novel EGF-like repeat-containing protein targeted to dendrites of developing and adult central nervous system neurons. J Biol Chem 2002; 277: 25400-25407. – reference: Eiraku M, Tohgo A, Ono K, et al. DNER acts as a neuron-specific Notch ligand during Bergmann glial development. Nat Neurosci 2005; 8: 873-880. – reference: Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9: 776-785. – reference: de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist 2006; 11: 292-305. – reference: Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011; 77: 1698-1701. – reference: Sillevis Smitt P, Kinoshita A, De Leeuw B, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 2000; 342: 21-27. – reference: Graus F, Dalmau J, Valldeoriola F, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmunol 1997; 74: 55-61. – reference: Nishizumi H, Komiyama T, Miyabayashi T, et al. BET, a novel neuronal transmembrane protein with multiple EGF-like motifs. Neuroreport 2002; 13: 909-915. – reference: Tohgo A, Eiraku M, Miyazaki T, et al. Impaired cerebellar functions in mutant mice lacking DNER. Mol Cell Neurosci 2006; 31: 326-333. – reference: Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322: 1844-1851. – reference: Hoogenraad CC, Feliu-Mojer MI, Spangler SA, et al. Liprinalpha1 degradation by calcium/calmodulin-dependent protein kinase II regulates LAR receptor tyrosine phosphatase distribution and dendrite development. Dev Cell 2007; 12: 587-602. – reference: Hammack J, Kotanides H, Rosenblum MK, et al. Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease. Neurology 1992; 42: 1938-1943. – reference: Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667. – reference: Horwich L, Buxton PH, Ryan GM. Cerebellar degeneration with Hodgkin's disease. J Neurol Neurosurg Psychiatry 1966; 29: 45-51. – reference: Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67-76. – reference: Briani C, Vitaliani R, Grisold W, et al. Spectrum of paraneoplastic disease associated with lymphoma. Neurology 2011; 76: 705-710. – reference: Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin disease. An immunological study. Arch Neurol 1976; 33: 660-661. – reference: Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15: 2866-2872. – reference: Keime-Guibert F, Graus F, Broet P, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology 1999; 53: 1719-1723. – reference: Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36. – reference: Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60: 230-234. – volume: 61 start-page: 25 year: 2007 end-page: 36 article-title: Paraneoplastic anti‐N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma publication-title: Ann Neurol – volume: 12 start-page: 587 year: 2007 end-page: 602 article-title: Liprinalpha1 degradation by calcium/calmodulin‐dependent protein kinase II regulates LAR receptor tyrosine phosphatase distribution and dendrite development publication-title: Dev Cell – volume: 277 start-page: 25400 year: 2002 end-page: 25407 article-title: Delta/Notch‐like epidermal growth factor (EGF)‐related receptor, a novel EGF‐like repeat‐containing protein targeted to dendrites of developing and adult central nervous system neurons publication-title: J Biol Chem – volume: 342 start-page: 21 year: 2000 end-page: 27 article-title: Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor publication-title: N Engl J Med – volume: 30 start-page: 5866 year: 2010 end-page: 5875 article-title: Cellular and synaptic mechanisms of anti‐NMDA receptor encephalitis publication-title: J Neurosci – volume: 13 start-page: 909 year: 2002 end-page: 915 article-title: BET, a novel neuronal transmembrane protein with multiple EGF‐like motifs publication-title: Neuroreport – volume: 322 start-page: 1844 year: 1990 end-page: 1851 article-title: Selective expression of Purkinje‐cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration publication-title: N Engl J Med – volume: 96 start-page: 1 year: 1998 end-page: 7 article-title: Localization of the neuronal antigen recognized by anti‐Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system publication-title: Acta Neuropathol – volume: 53 start-page: 1719 year: 1999 end-page: 1723 article-title: Clinical outcome of patients with anti‐Hu‐associated encephalomyelitis after treatment of the tumor publication-title: Neurology – volume: 15 start-page: 2866 year: 1997 end-page: 2872 article-title: Anti‐Hu antibodies in patients with small‐cell lung cancer: association with complete response to therapy and improved survival publication-title: J Clin Oncol – volume: 9 start-page: 776 year: 2010 end-page: 785 article-title: Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series publication-title: Lancet Neurol – volume: 65 start-page: 424 year: 2009 end-page: 434 article-title: AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location publication-title: Ann Neurol – volume: 8 start-page: 873 year: 2005 end-page: 880 article-title: DNER acts as a neuron‐specific Notch ligand during Bergmann glial development publication-title: Nat Neurosci – volume: 29 start-page: 45 year: 1966 end-page: 51 article-title: Cerebellar degeneration with Hodgkin's disease publication-title: J Neurol Neurosurg Psychiatry – volume: 33 start-page: 660 year: 1976 end-page: 661 article-title: Cerebellar degeneration with Hodgkin disease. An immunological study publication-title: Arch Neurol – volume: 11 start-page: 292 year: 2006 end-page: 305 article-title: Managing paraneoplastic neurological disorders publication-title: Oncologist – volume: 31 start-page: 326 year: 2006 end-page: 333 article-title: Impaired cerebellar functions in mutant mice lacking DNER publication-title: Mol Cell Neurosci – volume: 126 start-page: 1409 year: 2003 end-page: 1418 article-title: Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients publication-title: Brain – volume: 9 start-page: 67 year: 2010 end-page: 76 article-title: Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen publication-title: Lancet Neurol – volume: 42 start-page: 1938 year: 1992 end-page: 1943 article-title: Paraneoplastic cerebellar degeneration. II. Clinical and immunologic findings in 21 patients with Hodgkin's disease publication-title: Neurology – volume: 133 start-page: 1655 year: 2010 end-page: 1667 article-title: N‐methyl‐D‐aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non‐paraneoplastic disorder of both sexes publication-title: Brain – year: 1995 – volume: 60 start-page: 230 year: 2003 end-page: 234 article-title: Anti‐Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease publication-title: Neurology – volume: 77 start-page: 1698 year: 2011 end-page: 1701 article-title: Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome publication-title: Neurology – volume: 76 start-page: 705 year: 2011 end-page: 710 article-title: Spectrum of paraneoplastic disease associated with lymphoma publication-title: Neurology – volume: 74 start-page: 55 year: 1997 end-page: 61 article-title: Immunological characterization of a neuronal antibody (anti‐Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease publication-title: J Neuroimmunol – volume: 7 start-page: 327 year: 2008 end-page: 340 article-title: Paraneoplastic syndromes of the CNS publication-title: Lancet Neurol – ident: e_1_2_6_11_2 doi: 10.1074/jbc.M110793200 – ident: e_1_2_6_8_2 doi: 10.1007/s004010050853 – ident: e_1_2_6_10_2 doi: 10.1212/WNL.53.8.1719 – ident: e_1_2_6_27_2 doi: 10.1016/S1474-4422(08)70060-7 – ident: e_1_2_6_13_2 doi: 10.1212/WNL.42.10.1938 – ident: e_1_2_6_4_2 doi: 10.1212/WNL.0b013e31820d62eb – ident: e_1_2_6_17_2 doi: 10.1002/ana.21050 – ident: e_1_2_6_19_2 doi: 10.1016/S1474-4422(09)70324-2 – ident: e_1_2_6_24_2 doi: 10.1634/theoncologist.11-3-292 – ident: e_1_2_6_20_2 doi: 10.1212/WNL.0b013e3182364a44 – ident: e_1_2_6_9_2 doi: 10.1212/01.WNL.0000041495.87539.98 – ident: e_1_2_6_18_2 doi: 10.1002/ana.21589 – ident: e_1_2_6_6_2 doi: 10.1001/archneur.1976.00500090066014 – ident: e_1_2_6_12_2 doi: 10.1016/j.devcel.2007.02.006 – ident: e_1_2_6_28_2 doi: 10.1523/JNEUROSCI.0167-10.2010 – ident: e_1_2_6_15_2 doi: 10.1097/00001756-200205070-00035 – ident: e_1_2_6_14_2 doi: 10.1056/NEJM199006283222604 – ident: e_1_2_6_7_2 doi: 10.1016/S0165-5728(96)00205-6 – ident: e_1_2_6_23_2 doi: 10.1200/JCO.1997.15.8.2866 – ident: e_1_2_6_26_2 doi: 10.1038/nn1492 – ident: e_1_2_6_5_2 doi: 10.1136/jnnp.29.1.45 – ident: e_1_2_6_25_2 doi: 10.1016/j.mcn.2005.10.003 – ident: e_1_2_6_21_2 doi: 10.1016/S1474-4422(10)70137-X – ident: e_1_2_6_3_2 doi: 10.1093/brain/awg133 – ident: e_1_2_6_16_2 doi: 10.1056/NEJM200001063420104 – ident: e_1_2_6_22_2 doi: 10.1093/brain/awq113 – volume-title: Paraneoplastic syndromes year: 1995 ident: e_1_2_6_2_2 |
SSID | ssj0009610 |
Score | 2.4432793 |
Snippet | Objective:
Anti‐Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however,... Anti-Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr... Objective: Anti-Tr is among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined with Hodgkin lymphoma (HL); however,... |
SourceID | proquest pubmed pascalfrancis crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 815 |
SubjectTerms | Adult Aged Animals Autoantibodies - blood beta-Galactosidase - metabolism Biological and medical sciences Cell Line, Transformed Child Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Epidermal growth factor Female Glycosylation Hippocampus - pathology Hodgkin Disease - immunology Humans Male Mass Spectrometry Medical research Medical sciences Middle Aged Nerve Tissue Proteins - immunology Nerve Tissue Proteins - metabolism Neurology Neurons - metabolism Paraneoplastic Cerebellar Degeneration - immunology Paraneoplastic Cerebellar Degeneration - metabolism Rats Receptors, Cell Surface - immunology Receptors, Cell Surface - metabolism Rodents Tandem Repeat Sequences - immunology Young Adult |
Title | Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration |
URI | https://api.istex.fr/ark:/67375/WNG-FHLSR5HJ-Z/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fana.23550 https://www.ncbi.nlm.nih.gov/pubmed/22447725 https://www.proquest.com/docview/1516475743 https://www.proquest.com/docview/1021980779 https://www.proquest.com/docview/1520390834 |
Volume | 71 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA_HCeKL3x_V84gici_d7VeaFp8WcV0Obx_OOzxECEmanMcu3WO3C-KT7774N_qXOJO0XVZOEd9KO20z00nySzPzG0JeRKUBN4lUaKWSYSa5ChXME6HlDOcPxSOJicJH03xymh2esbMd8qrLhfH8EP0PN-wZbrzGDi7VarghDZW1HCQwW-J6HWO1EBAdb6ijytwxEeA2W8jiNOtYhaJk2N-5NRddQ7N-wdhIuQLzWF_X4irguY1j3UQ0vkU-dSr4-JPZYN2ogf76G7vjf-p4m9xsASodeY-6Q3ZMfZdcP2q34O-R7z6117b_-ujC0srMGzmsF-AAP7_9mF_MDDVYeBbG_Dk9h3V-85n6uj5w2SXPmIrCSGsu4RSVKwoglJ7AETwX_Jle1BQZyWsMbpfII021WRrcIZFLeNm5Y8rGl98np-M3J68nYVvRIdQMtMBydjKzcWFZFRsWF6ZINXwoxsuiyhXTOucGEIdNbFXwQgN4SFPAFDxTlTW8itIHZLde1OYRobGFR7pE2chmicqKPC8rAHe5hhWxSpKAHHTfVuiW7hyrbsyFJ2pOBBhXOOMG5Hkveuk5Pq4SeukcpJeQyxkGxXEmPkzfivHk3ftjNjkUHwOyv-VB_Q1YCiDnGQvIXudSoh0wVgKAFyjDAM8F5Fl_Gbo67t-gwdcgA3isLCLOy7_IsCRKS8DVWUAeenfdNACgHCymoAEHzun-rKwYTUfu4PG_iz4hNwBMJj6Mbo_sNsu1eQqArVH7rmf-AiPSPQQ |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NctMwEN4p7Qz0wj_UUIpggOnFiWNbln3gkKGEtE1yKOm0w0VItlQ6yTid_EyBE3cuPAivwkvwJKwsx5kwheHSAzePvZZlaVffSlp9C_DMSxSqiSddLaRwQ8GkKxEnXM2owQ_JPGEOCnd7Ufsw3DumxyvwfX4WxvJDVAtuxjKK8doYuFmQri9YQ0Uuaj7CpVeGVO6rT-c4YZu83N3B3n3u-63X_Vdtt8wp4KYURU1CNRHqRqxp1lC0Eas4SBNEdZbEWSRpmkZMIeZpX2cxi1OEryBAVGOhzLRimRdguVdgzWQQN0z9OwcLsiosxrM7o6FLG0E45zHy_HpV1SX0WzMd-dFEY4oJdoi2mTQucnWXPecC-lo34Me80WzEy6A2m8pa-vk3Psn_pVVvwvXSBydNazS3YEXlt-Fqt4wyuANf7ellXS5nkpEmmRpORT0foY7__PJteDpQRJncughrQ3IyHp1PPxCbuggfF-eDVEYQTNQZ3iJiQtDPJn28wnLRZMlpTgzpem7i94WhyiapGiuzCSTG-LGTggzcfPwuHF5KU9yD1XyUqw0gDY1FFmeBPR36MoyjKMnQf41SnPRL33dge65MPC0Z3U1ikSG3XNQ-x87kRWc68LQSPbM0JhcJvSg0spIQ44GJ-2OUH_Xe8Fa78_aAtvf4Owe2llS2esFkO4hYSB3YnOswL8fECUffEn-GosvqwJPqMY5mZovKNPgMZdDlTGKPseQvMtT3ggSnDqED9619LCqA3irOF7EC24WW__lnebPXLC4e_LvoY7jW7nc7vLPb238I6-g7-zZqcBNWp-OZeoT-6VRuFcMCgfeXbTG_ALQkmRg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9MwGLbGJk1c-P4IjGEQoF3SOokdJwcOFaV0XxUam5i4GDuxx9QqrfqhASfuXPgf_BV-Bb-E13GaqmggLjtwi5q3jmO_r5_H8fuB0BOSalATonwjlfSp5MpXgBO-4czih-JE2kDh_V7cPaI7x-x4BX2fx8K4_BD1BzdrGeV6bQ18lJvmImmoLGQjBLQklUflrv50Bvu1yfPtNkzu0zDsvDx80fWrkgJ-xkDU1lOT1ASJYXmgWZDoJMpSAHWeJnmsWJbFXAPkmdDkCU8yQK8oAlDjVOVG85xE0O4ltEZjkto6Ee2DRa4qaIa4g1HqsyCi8zRGJGzWXV0CvzU7jx-tM6acwHwYV0jjPKa7TJxL5OtcRT_mY-YcXvqN2VQ1ss-_pZP8Twb1GrpSMXDcciZzHa3o4gZa3698DG6iry522VQfM_HQ4FwPprJZDEHDf375Njjta6xtZV0AtQE-GQ_Pph-wK1wEt8voIJ1jgBI9gp-wnGBg2fgQrqBdMFh8WmCbcr2w3vvSJsrGmR5rewQkx_CwkzIVuH34LXR0IUNxG60Ww0LfRTgw0GQZCUwMDRVN4jjNgb3GGWz5VRh6aGuuSyKr8rnbsiID4TJRhwImU5ST6aHHtejIJTE5T-hZqZC1hBz3rdcfZ-Jt75XodPfeHLDujnjnoc0lja3_YGsdxJwyD23MVVhUK-JEALOEl2FAWD30qL4Na5k9oLIDPgMZIJxpQjhP_yLDQhKlsHGgHrrjzGPRAeCqsFuEDmyVSv7nlxWtXqu8uPfvog_R-ut2R-xt93bvo8tAnEPnMriBVqfjmX4A5HSqNstFAaP3F20wvwBC75fH |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+delta%2Fnotch-like+epidermal+growth+factor-related+receptor+as+the+Tr+antigen+in+paraneoplastic+cerebellar+degeneration&rft.jtitle=Annals+of+neurology&rft.au=de+Graaff%2C+Esther&rft.au=Maat%2C+Peter&rft.au=Hulsenboom%2C+Esther&rft.au=van+den+Berg%2C+Robert&rft.date=2012-06-01&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0364-5134&rft.eissn=1531-8249&rft.volume=71&rft.issue=6&rft.spage=815&rft.epage=824&rft_id=info:doi/10.1002%2Fana.23550&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_FHLSR5HJ_Z |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0364-5134&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0364-5134&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0364-5134&client=summon |